
Quarterly report 2022-Q3
added 11-10-2022
Oyster Point Pharma Market Cap 2011-2026 | OYST
As of March 27, 2026 Oyster Point Pharma has a market cap of $ 300 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Oyster Point Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 286 M | 86.1 M | 146 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 286 M | 86.1 M | 173 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Ultragenyx Pharmaceutical
RARE
|
2.01 B | $ 19.23 | -3.85 % | $ 1.9 B | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
RedHill Biopharma Ltd.
RDHL
|
1.2 B | $ 0.8 | 0.89 % | $ 428 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
10.8 B | $ 13.56 | -1.56 % | $ 2.25 B | ||
|
Regeneron Pharmaceuticals
REGN
|
81.3 B | $ 742.02 | -1.94 % | $ 77.6 B | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
Replimune Group
REPL
|
601 M | $ 7.22 | -4.24 % | $ 582 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
REGENXBIO
RGNX
|
444 M | $ 7.88 | -4.6 % | $ 406 M | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | ||
|
Rigel Pharmaceuticals
RIGL
|
598 M | $ 26.2 | -0.64 % | $ 471 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | ||
|
Avidity Biosciences
RNA
|
10 B | $ 13.09 | -0.08 % | $ 1.8 B | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 78.52 | -4.13 % | $ 5.1 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
2.48 B | $ 12.57 | -9.96 % | $ 1.91 B | ||
|
Sana Biotechnology
SANA
|
995 M | $ 2.78 | -8.42 % | $ 704 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
SIGA Technologies
SIGA
|
404 M | $ 5.35 | 7.76 % | $ 383 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 321.71 | -1.96 % | $ 42.1 B | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
1.82 M | - | - | $ 3.74 B | ||
|
Silence Therapeutics plc
SLN
|
1.63 B | $ 4.8 | -9.6 % | $ 622 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
18.3 M | $ 1.08 | -0.92 % | $ 22.2 M | ||
|
Enochian Biosciences
ENOB
|
116 M | - | - | $ 40.5 M |